

Pharmaceuticals

The Recyclable Inhaler

Challenge Introduction

Chiesi is committed to be NetZero by 2030. A big step will be the development of the carbon minimal inhaler (pMDI) with a propellant that delivers a 90% carbon emission reduction. What we don't know yet is how we can improve the use of plastics in our inhaler. As the plastic is in contact with the active ingredient, we are limited to use recycled plastic for our inhalers, and we cannot use the plastics of a used inhaler to be recycled. Towards 2030 EU regulation will dictate that to a certain extent recycled plastics need to be used and the products need to be recycled.

What would the pMDI (pressurized metered dose inhaler) of the future look like that is built of recycled material and can be recycled? Can you create a cradle to grave pMDI?



Who is behind this initiative?

Chiesi Pharmaceuticals is a family-owned health company - not only for people but also for the environment. We do our best to mitigate climate change and environmental damage; healthy people on a healthy planet. One of our goals is to make our medicine carbon-neutral.

For instance, we are investing a quarter of a billion in developing an inhaler for lung patients with almost zero CO2 emissions. We are also looking at how to reduce the (packaging) waste of our medicines and what we can do to reduce the impact of our medicines on the environment. Furthermore, Chiesi also develops medicines for people with lung diseases and additionally plays a major role in supporting the Smoke-Free Generation in 2030 in The Netherlands. Our efforts are externally validated as B-corp.

In this challenge you will be supported by **Maarten van den Broek** and his Chiesi colleagues. Maarten is Communication & Sustainability Director at Chiesi Benelux.



How does this challenge enhance connections?

Chiesi - being a B-Corp - is actively finding ways to pursue the collective good. They do this not only by actively pursuing ways to become more sustainable, but also putting a lot of effort into attaining a Smoke-Free Generation by 2030 in The Netherlands. Furthermore, Chiesi also focuses specifically on rare diseases, striving to create a world where it is common to have a therapy for all diseases.

